Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis

Lendvai, Gábor; Szekerczés, Tímea; Illyés, Idikó; Dóra, Réka; Kontsek, Endre; Gógl, A; Kiss, András; Werling, Klára; Kovalszky, Ilona; Schaff, Zsuzsa; Borka, Katalin

doi:10.1007/s12253-018-0491-8

Cited by 88 publications

(93 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several epidemiological reports have shown an increase in global occurrence (up to 10 folds) and mortality for iCCA, whereas the incidence for eCCA remained either unchanged or slightly decreased [15][16][17][18][19]. CCA is mainly diagnosed in an advanced clinical stage of the disease, when curative treatment is generally unsuccessful [20]. This is in part due to the lack of clinical manifestation of the tumor in the early stage, especially in case of iCCA, and in part to the absence of specific and sensitive biomarkers.…”

Section: Of 28mentioning

confidence: 99%

Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives

Pastore

Lori

Gentilini

et al. 2020

Cells

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a deadly tumor without an effective therapy. Unique metabolic and bioenergetics features are important hallmarks of tumor cells. Metabolic plasticity allows cancer cells to survive in poor nutrient environments and maximize cell growth by sustaining survival, proliferation, and metastasis. In recent years, an increasing number of studies have shown that specific signaling networks contribute to malignant tumor onset by reprogramming metabolic traits. Several evidences demonstrate that numerous metabolic mediators represent key-players of CCA progression by regulating many signaling pathways. Besides the well-known Warburg effect, several other different pathways involving carbohydrates, proteins, lipids, and nucleic acids metabolism are altered in CCA. The goal of this review is to highlight the main metabolic processes involved in the cholangio-carcinogeneis that might be considered as potential novel druggable candidates for this disease.

show abstract

Section: Of 28mentioning

confidence: 99%

Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives

Pastore

Lori

Gentilini

et al. 2020

Cells

View full text Add to dashboard Cite

show abstract

“…However, the research on the role of circ-SMARCA5 in ICC has not conducted yet. Considering the similarities of cellular origin, genomic mutations, risk factors between ICC and HCC, we speculated that circ-SMARCA5 might also be aberrantly expressed in ICC tissues, and correlated with tumor features in ICC patients [15,16]. We found that circ-SMARCA5 was downregulated in ICC tumor tissues compared with adjacent tissues, and was negatively associated with ECOG performance score, TNM stage and abnormal CA199 status in ICC patients.…”

Section: Discussionmentioning

confidence: 84%

“…And in vivo experiments reveals that circ-SMARCA5 inhibits HCC cell proliferation and migration [14]. Considering that ICC and HCC share some similarities in molecular profiles, dominant risk factors and clinical manifestations, therefore, we speculated that circ-SMARCA5 might be involved in the ICC development and progression [15,16]. In the current study, we aimed to investigate the correlation of circ-SMARCA5 expression with clinical characteristics and survival profiles in ICC patients, and further conducted the cellular experiments to discover the role of circ-SMARCA5 in regulating cell proliferation and drug sensitivity of ICC.…”

Section: Introductionmentioning

confidence: 97%

Circular RNA SMARCA5 correlates with favorable clinical tumor features and prognosis, and increases chemotherapy sensitivity in intrahepatic cholangiocarcinoma

Fang

2019

Preprint

View full text Add to dashboard Cite

Background This present study aimed to investigate the correlation of circular RNA SMARCA5 (circ-SMARCA5) with clinicopathological features and overall survival (OS), and the effect of circ-SMARCA5 on cell proliferation and chemotherapy sensitivity to cisplatin/gemcitabine in intrahepatic cholangiocarcinoma (ICC).Methods Totally 92 primary ICC patients who underwent resection were recruited, and their tumor tissues, adjacent tissues were collected for circ-SMARCA5 detection. The effect of circ-SMARCA5 on cell proliferation and chemotherapy sensitivity was detected after circ-SMARCA5 overexpression plasmids transfection into TFK-1 and HuH-28 ICC cells.Results Circ-SMARCA5 expression was reduced in ICC tumor tissues compared to adjacent tissues. Tumor circ-SMARCA5 high expression was negatively associated with Eastern Cooperative Oncology Group performance score, T stage, N stage, TNM stage and abnormal CA199 status. Furthermore, OS was increased in patients with tumor circ-SMARCA5 high expression compared with those with low expression, and further multivariate Cox’s regression demonstrated that tumor circ-SMARCA5 high expression was an independent predictive factor for longer OS. In TFK-1 and HuH-28 ICC cells, circ-SMARCA5 upregulation decreased cell proliferation, reduced relative cell viability in cisplatin-treated as well as gemcitabine-treated cells, and also decreased inhibitory concentration by 50% value (IC50) of cisplatin and gemcitabine.Conclusions The correlation of circ-SMARCA5 with favorable clinical tumor features, survival profile, and its promoting effect on chemotherapy sensitivity imply its potential as a valuable biomarker in monitoring disease progression and prognosis of ICC.

show abstract

“…However, the research on the role of circ‐SMARCA5 in ICC has not conducted yet. Considering the similarities of cellular origin, genomic mutations, and risk factors between ICC and HCC, we speculated that circ‐SMARCA5 might also be aberrantly expressed in ICC tissues and correlated with tumor features in patients with ICC . We found that circ‐SMARCA5 was downregulated in ICC tumor tissues compared with adjacent tissues and was negatively associated with ECOG performance score, TNM stage, and abnormal CA199 status in patients with ICC.…”

Section: Discussionmentioning

confidence: 88%

“…And in vivo experiments reveal that circ‐SMARCA5 inhibits HCC cell proliferation and migration . Considering that ICC and HCC share some similarities in molecular profiles, dominant risk factors, and clinical manifestations, therefore, we speculated that circ‐SMARCA5 might be involved in the ICC development and progression . In the current study, we aimed to investigate the correlation of circ‐SMARCA5 expression with clinical characteristics and survival profiles in patients with ICC and further conducted the cellular experiments to discover the role of circ‐SMARCA5 in regulating cell proliferation and chemosensitivity of ICC.…”

Section: Introductionmentioning

confidence: 99%

Circular RNA SMARCA5 correlates with favorable clinical tumor features and prognosis, and increases chemotherapy sensitivity in intrahepatic cholangiocarcinoma

Fang

2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Objective: This present study aimed to investigate the correlation of circular RNA SMARCA5 (circ-SMARCA5) with clinicopathological features and overall survival (OS), and the effect of circ-SMARCA5 on cell proliferation and chemotherapy sensitivity to cisplatin/gemcitabine in intrahepatic cholangiocarcinoma (ICC). Methods:Totally 92 primary ICC patients who underwent resection were recruited, and their tumor tissues and adjacent tissues were collected for circ-SMARCA5 detection. The effect of circ-SMARCA5 on cell proliferation and chemotherapy sensitivity was detected after circ-SMARCA5 overexpression plasmid transfection into TFK-1 and HuH-28 ICC cells.Results: Circ-SMARCA5 expression was reduced in ICC tumor tissues compared to adjacent tissues. Tumor circ-SMARCA5 high expression was negatively associated with Eastern Cooperative Oncology Group performance score, T stage, N stage, TNM stage, and abnormal CA199 status. Furthermore, OS was increased in patients with tumor circ-SMARCA5 high expression compared with those with low expression, and further multivariate Cox's regression demonstrated that tumor circ-SMARCA5 high expression was an independent predictive factor for longer OS. In TFK-1 and HuH-28 ICC cells, circ-SMARCA5 upregulation decreased cell proliferation, reduced relative cell viability in cisplatin-treated as well as gemcitabine-treated cells, and also decreased inhibitory concentration by 50% value (IC 50 ) of cisplatin and gemcitabine. Conclusion:The correlation of circ-SMARCA5 with favorable clinical tumor features, survival profile, and its promoting effect on chemotherapy sensitivity implies its potential as a valuable biomarker in monitoring disease progression and prognosis of ICC. K E Y W O R D Scell proliferation, chemotherapy sensitivity, circular RNA SMARCA5, intrahepatic cholangiocarcinoma, prognosis

show abstract

Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis

Cited by 88 publications

References 99 publications

Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives

Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives

Circular RNA SMARCA5 correlates with favorable clinical tumor features and prognosis, and increases chemotherapy sensitivity in intrahepatic cholangiocarcinoma

Circular RNA SMARCA5 correlates with favorable clinical tumor features and prognosis, and increases chemotherapy sensitivity in intrahepatic cholangiocarcinoma

Contact Info

Product

Resources

About